Ibnsina Pharma results, Q1 2025
Net profit, assets, equity and cash flow for Q1 2025, against the same period a year earlier, from the published financial statements.
Net profit182 millionEGP · +85.3% vs the same period a year earlier
Total assets32.69 billionEGP · +58.3% vs the same period a year earlier
Shareholders' equity2.18 billionEGP · +40.7% vs the same period a year earlier
Operating cash flow-1.51 billionEGP · −282.1% vs the same period a year earlier
In short
- Ibnsina Pharma's net profit for Q1 2025 was about 182 million EGP, up +85.3% from 98.14 million EGP in Q1 2024.
- Total assets at the end of Q1 2025 were about 32.69 billion EGP, and shareholders' equity about 2.18 billion EGP.
- Operating cash flow for Q1 2025 was negative at 1.51 billion EGP.
Key lines against the same period a year earlier
This periodQ1 2024Change
Net profit182 million98.14 million+85.3%
Gross profit1.46 billion811 million+80.5%
Total assets32.69 billion20.66 billion+58.3%
Total liabilities30.51 billion19.11 billion+59.7%
Shareholders' equity2.18 billion1.55 billion+40.7%
Total liabilities and equity32.69 billion20.66 billion+58.3%
Operating cash flow-1.51 billion-396 million−282.1%
Investing cash flow-55.32 million-58.29 million+5.1%
Financing cash flow2.19 billion265 million+724.0%
Net change in cash620 million-188 million+429.1%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Ibnsina Pharma's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy